501 related articles for article (PubMed ID: 31211526)
21. Real-world economic burden of hepatitis C and impact of direct-acting antivirals in France: A nationwide claims data analysis.
Lam L; Carrieri P; Hejblum G; Bellet J; Bourlière M; Carrat F
Liver Int; 2024 May; 44(5):1233-1242. PubMed ID: 38375961
[TBL] [Abstract][Full Text] [Related]
22. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
Gray E; O'Leary A; Kieran JA; Fogarty E; Dowling T; Norris S;
J Viral Hepat; 2016 Sep; 23(9):677-86. PubMed ID: 26996144
[TBL] [Abstract][Full Text] [Related]
23. Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.
Auty SG; Shafer PR; Griffith KN
JAMA Health Forum; 2021 Aug; 2(8):e212291. PubMed ID: 35977192
[TBL] [Abstract][Full Text] [Related]
24. Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis.
Herink MC; Geddes J; Vo K; Zaman A; Hartung DM
J Manag Care Spec Pharm; 2021 Jul; 27(7):856-864. PubMed ID: 34185560
[No Abstract] [Full Text] [Related]
25. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
[TBL] [Abstract][Full Text] [Related]
27. Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences.
Ward T; Gordon J; Bennett H; Webster S; Sugrue D; Jones B; Brenner M; McEwan P
Public Health; 2016 Dec; 141():42-51. PubMed ID: 27932014
[TBL] [Abstract][Full Text] [Related]
28. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.
Clements KM; Clark RE; Lavitas P; Kunte P; Graham CS; O'Connell E; Lenz K; Jeffrey P
J Manag Care Spec Pharm; 2016 Jun; 22(6):714-722b. PubMed ID: 27231798
[TBL] [Abstract][Full Text] [Related]
29. Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe.
Cacoub P; Buggisch P; Carrión JA; Cooke GS; Zignego AL; Beckerman R; Younossi Z
J Viral Hepat; 2018 Jul; 25(7):811-817. PubMed ID: 29476572
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype.
Goolsby Hunter A; Rosenblatt L; Patel C; Blauer-Peterson C; Anduze-Faris B
Curr Med Res Opin; 2017 May; 33(5):829-836. PubMed ID: 28128648
[TBL] [Abstract][Full Text] [Related]
31. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
Connolly MP; Kotsopoulos N; Ustianowski A
J Med Econ; 2018 Jan; 21(1):19-26. PubMed ID: 28830254
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
33. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
Le TK; Macaulay D; Kalsekar A; Yuan Y; Sorg RA; Wei J; Wu EQ
Clin Ther; 2015 Aug; 37(8):1713-25.e3. PubMed ID: 26111918
[TBL] [Abstract][Full Text] [Related]
34. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
35. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
36. Age-based health and economic burden of skin and soft tissue infections in the United States, 2000 and 2012.
Tun K; Shurko JF; Ryan L; Lee GC
PLoS One; 2018; 13(11):e0206893. PubMed ID: 30383858
[TBL] [Abstract][Full Text] [Related]
37. Burden of disease and cost of chronic hepatitis C infection in Canada.
Myers RP; Krajden M; Bilodeau M; Kaita K; Marotta P; Peltekian K; Ramji A; Estes C; Razavi H; Sherman M
Can J Gastroenterol Hepatol; 2014 May; 28(5):243-50. PubMed ID: 24839620
[TBL] [Abstract][Full Text] [Related]
38. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
39. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
40. Cost of care for Medicaid recipients with serious mental illness and HIV infection or AIDS.
Rothbard AB; Metraux S; Blank MB
Psychiatr Serv; 2003 Sep; 54(9):1240-6. PubMed ID: 12954940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]